Q3 EPS Estimates for Purple Biotech Cut by HC Wainwright

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) – Investment analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Purple Biotech in a research note issued on Friday, August 7th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($2.88) for the quarter, down from their prior forecast of ($1.73). The consensus estimate for Purple Biotech’s current full-year earnings is ($5.31) per share. HC Wainwright also issued estimates for Purple Biotech’s Q4 2026 earnings at ($3.00) EPS, FY2026 earnings at ($5.73) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($0.51) EPS, FY2029 earnings at ($0.37) EPS and FY2030 earnings at ($0.12) EPS.

Several other equities research analysts have also commented on PPBT. Zacks Research upgraded Purple Biotech from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Weiss Ratings raised Purple Biotech from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Purple Biotech presently has an average rating of “Hold” and an average price target of $30.00.

Purple Biotech Trading Up 4.9%

PPBT stock opened at $1.50 on Tuesday. The firm has a market cap of $1.40 million, a PE ratio of -0.06 and a beta of 0.67. The stock has a 50-day moving average price of $1.76 and a 200-day moving average price of $3.57. Purple Biotech has a 1-year low of $1.16 and a 1-year high of $24.00.

Purple Biotech (NASDAQ:PPBT) last issued its quarterly earnings results on Saturday, May 16th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.29.

Hedge Funds Weigh In On Purple Biotech

A hedge fund recently bought a new stake in Purple Biotech stock. SmartHarvest Portfolios LLC purchased a new stake in shares of Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 47,454 shares of the company’s stock, valued at approximately $31,000. SmartHarvest Portfolios LLC owned about 0.37% of Purple Biotech as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.64% of the company’s stock.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.